Aficamten
Modify Date: 2024-01-02 15:27:09
Aficamten structure
|
Common Name | Aficamten | ||
|---|---|---|---|---|
| CAS Number | 2364554-48-1 | Molecular Weight | 337.38 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H19N5O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AficamtenAficamten (CK-274) is a novel cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM)[1]. |
| Name | Aficamten |
|---|---|
| Synonym | More Synonyms |
| Description | Aficamten (CK-274) is a novel cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM)[1]. |
|---|---|
| Related Catalog | |
| In Vivo | "Aficamten is a next-generation cardiac myosin inhibitor that provides a projected human half-life appropriate for once a day dosing, reaching steady state within two weeks, and demonstrates a wide therapeutic window in vivo with a clear PK/PD relationship[1]. Aficamten exhibits moderate oral bioavailability (mouse 98%, rat 55%, rat 58%,rat 79%, dog 45%, monkey 41%) following oral administration (mouse 1 mg/kg, rat 2 mg/kg, rat 3 mg/kg, rat 8 mg/kg, dog 1 mg/kg and monkey 1 mg/kg)[1]. Aficamten exhibits terminal elimination half-lives (mouse 4.5 h, rat 3.0 h, dog 33.8 h and, monkey 8.1 h) following intravenous administration (mouse 0.5 mg/kg, rat 1 mg/kg, dog 1 mg/kg and monkey 1.0 mg/kg)[1]." |
| References |
| Molecular Formula | C18H19N5O2 |
|---|---|
| Molecular Weight | 337.38 |
| CK-274 |